《Induction of Akt activitychemotherapy confers acquired resistance.doc》由会员分享，可在线阅读，更多相关《Induction of Akt activitychemotherapy confers acquired resistance.doc（5页珍藏版）》请在三一办公上搜索。
1、Author(s): Huang, WC (Huang, Wei-Chien); Hung, MC (Hung, Mien-Chie)Title: Induction of Akt Activity by Chemotherapy Confers Acquired ResistanceSource: JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 108 (3): 180-194 MAR 2009Language: EnglishDocument Type: ReviewAuthor Keywords: Akt; antiapoptosis; canc
2、er; drug resistanceKeyWords Plus: NF-KAPPA-B; OVARIAN-CANCER CELLS; PLASMINOGEN-ACTIVATOR INHIBITOR-1; GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE-B; X-LINKED INHIBITOR; PHOSPHOINOSITIDE 3-KINASE/AKT PATHWAY; CISPLATIN-INDUCED APOPTOSIS; ETOPOSIDE-INDUCED APOPTOSIS; WILD-TYPE P53Abstract: Resistance to c
3、hemotherapy is a major cause of treatment failure in human cancer. Accumulating evidence has indicated that the acquisition of resistance to chemotherapeutic drugs involves the activation of the PI3K/Akt pathway, modulating Akt activity ill response to chemotherapy has been observed often ill chemor
4、esistant cancers. The potential molecular mechanisms by which chemotherapeutic agents activate the PI3K/Akt pathway arc emerging. Activation of this pathway evades the cytotoxic effects of chemotherpeutic agents via regulation of essential cellular functions such as protien synthesis, antiapoptosis,
5、 survival and proliferation in cancer flow chemotherapeutic agents induce Akt activation and how activated Akt confers chemoresistance through regulation of signaling networks are discussed in this review. Combining PI3K/Akt inhibitors with standard chemotherapy has been successful in increasing the
6、 efficacy of chemotherapeutic agents both in vivo and in vitro. Several small molecules have been developed to specifically target PI3K/Akt and other components of this pathway, which in combination with chemotherapy may be a valid approach mechanisms Of signaling networks for maintenance, of the Ak
7、t activity for cell survival. These regulatory mechanisms may limit the efficacy Of PI3K/Akt-targeted therapy; therefore, disruption of these mechanisms may be an effective strategy for development of novel anti-cancer therapies. J Formos Med Assoc 2009; 108(3); 180-194Addresses: Huang, Wei-Chien; H
8、ung, Mien-Chie China Med Univ & Hosp, Ctr Mol Med, Taichung 404, Taiwan; Huang, Wei-Chien; Hung, Mien-Chie China Med Univ & Hosp, Grad Inst Canc Biol, Taichung 404, Taiwan; Huang, Wei-Chien; Hung, Mien-Chie Asia Univ, Dept Biotechnol, Taichung, Taiwan; Hung, Mien-Chie Univ Texas MD Anderson Canc Ctr
9、, Dept Mol & Cellular Oncol, Houston, TX 77030 USAReprint Address: Huang, WC, China Med Univ & Hosp, Ctr Mol Med, Taichung 404, Taiwan.E-mail Address: whuangmail.cmu.edu.tw; mhungmdanderson.orgCited References: ACTOR B, 2002, GENE CHROMOSOME CANC, V34, P416.ANDJELKOVIC M, 1997, J BIOL CHEM, V272, P3
10、1515.ANDRE F, 2008, ANN ONCOL, V19, P315, DOI 10.1093/annonc/mdm429.ASHCROFT M, 2002, ONCOGENE, V21, P1955.ASSELIN E, 2001, CANCER RES, V61, P1862.BAJOU K, 1998, NAT MED, V4, P923.BALENDRAN A, 1999, CURR BIOL, V9, P393.BALENDRAN A, 2000, J BIOL CHEM, V275, P20806.BARBONE D, 2008, J BIOL CHEM, V283,
11、P13021, DOI 10.1074/jbc.M709698200.BELLACOSA A, 1995, INT J CANCER, V64, P280.BELYANSKAYA LL, 2005, INT J CANCER, V117, P755, DOI 10.1002/ijc.21242.BERTELSEN BI, 2006, INT J CANCER, V118, P1877, DOI 10.1002/ijc.21461.BEYER BCM, 2006, CANCER, V106, P1026, DOI 10.1002/cncr.21682.BIRCK A, 2000, J INVES
12、T DERMATOL, V114, P277.BOZULIC L, 2008, MOL CELL, V30, P203.BRAUNDULLAEUS RC, 2001, ARTERIOSCL THROM VAS, V21, P1152.BROZOVIC A, 2007, CANCER LETT, V251, P1, DOI 10.1016/j.canlet.2006.10.007.BRUNN GJ, 1996, EMBO J, V15, P5256.BYUN DS, 2003, INT J CANCER, V104, P318, DOI 10.1002/ijc.10962.CAMPBELL IG
13、, 2004, CANCER RES, V64, P7678.CAMPBELL IG, 2005, CLIN CANCER RES 1, V11, P7042, DOI 10.1158/1078-0432.CCR-05-1024.CARDONE MH, 1998, SCIENCE, V282, P1318.CHAZAUD B, 2002, AM J PATHOL, V160, P237.CHEKENYA M, 2008, ONCOGENE, V27, P5182, DOI 10.1038/onc.2008.157.CHENG GZ, 2007, CANCER RES, V67, P1979,
14、DOI 10.1158/0008-5472.CAN-06-1479.CHENG JQ, 1996, P NATL ACAD SCI USA, V93, P3636.CHOI BH, 2008, CANCER LETT, V259, P111, DOI 10.1016/j.canlet.2007.10.003.CLARK AS, 2002, MOL CANCER THER, V1, P707.DATTA SR, 1997, CELL, V91, P231.DELCOMMENNE M, 1998, P NATL ACAD SCI USA, V95, P11211.DELPESO L, 1997,
15、SCIENCE, V278, P687.DEMARCHI F, 2001, J BIOL CHEM, V276, P31738.DEMARCHI F, 2005, DRUG RESIST UPDATE, V8, P359, DOI 10.1016/j.drup.2005.12.001.DU KY, 1998, J BIOL CHEM, V273, P32377.EASTON JB, 2006, ONCOGENE, V25, P6436, DOI 10.1038/sj.onc.1209886.ERMOIAN RP, 2002, CLIN CANCER RES, V8, P1100.ERSTER
16、S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004.FENG JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200.FENG JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200.FINGAR DC, 2002, GENE DEV, V16, P1472.FRASER M, 2003, CANCER RES, V63, P7081.FRASER M, 20
17、08, INT J CANCER, V122, P534, DOI 10.1002/ijc.23086.GALLIA GL, 2006, MOL CANCER RES, V4, P709, DOI 10.1158/1541-7786.MCR-06-0172.GARCIA MG, 2009, LEUKEMIA RES, V33, P288, DOI 10.1016/j.leukres.2008.06.010.GARDAI SJ, 2004, J BIOL CHEM, V279, P21085, DOI 10.1074/jbc.M400063200.GRANDAGE VL, 2005, LEUKE
18、MIA, V19, P586, DOI 10.1038/sj.leu.2403653.GRONDAHLHANSEN J, 1993, CANCER RES, V53, P2513.GUERTIN DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007.GUSTIN JA, 2004, J BIOL CHEM, V279, P1615, DOI 10.1074/jbc.M306976200.HANADA M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapa
19、p.2003.11.009.HARIMA Y, 2001, INT J ONCOL, V18, P493.HENNESSY BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902.HILL MM, 2002, CURR BIOL, V12, P1251.HODKINSON PS, 2006, CELL DEATH DIFFER, V13, P1776, DOI 10.1038/sj.cdd.4401849.HOFFMAN WH, 2002, J BIOL CHEM, V277, P3247.HU MC, 2005, FUTURE
20、 ONCOL, V1, P67.HUANG H, 2001, J BIOL CHEM, V276, P38830.HUI RCY, 2008, MOL CELL BIOL, V28, P5886, DOI 10.1128/MCB.01265-07.JACINTO E, 2006, CELL, V127, P125.JAVLE MM, 2006, J GASTROEN HEPATOL, V21, P1744, DOI 10.1111/j.1440-1746.2006.04373.x.JEONG SJ, 2005, ONCOGENE, V24, P6719, DOI 10.1038/sj.onc.
21、1208825.JIANG BH, 2008, BBA-PROTEINS PROTEOM, V1784, P150, DOI 10.1016/j.bbapap.2007.09.008.KIM J, 2006, CANCER RES, V66, P784, DOI 10.1158/0008-5472.CAN-05-1316.KIM TJ, 2006, BRIT J CANCER, V94, P1678, DOI 10.1038/sj.bjc.6603180.KNOBBE CB, 2003, BRAIN PATHOL, V13, P507.KOHNO T, 1998, GENE CHROMOSOM
22、E CANC, V22, P152.KRAUS AC, 2002, ONCOGENE, V21, P8683, DOI 10.1038/sj.onc.1205939.KUO MT, 2002, ONCOGENE, V21, P1945.LEE JW, 2005, ONCOGENE, V24, P1477, DOI 10.1038/sj.onc.1208304.LEVINE AJ, 1997, CELL, V88, P323.LIMESAND KH, 2006, MOL CELL BIOL, V26, P8840, DOI 10.1128/MCB.01846-05.LIU LZ, 2007, C
23、ANCER RES, V67, P6325, DOI 10.1185/0008-5472.CAN-06-4261.LIU Q, 2004, J BIOL CHEM, V279, P52175.LIU SQ, 2006, DIGEST LIVER DIS, V38, P310, DOI 10.1016/j.dld.2006.01.012.LO HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575.LOPEZPAJARES V, 2008, J BIOL CHEM, V283, P13707, DOI 10.1074
24、/jbc.M710030200.LOPICCOLO J, 2008, DRUG RESIST UPDATE, V11, P32, DOI 10.1016/j.drup.2007.11.003.LYNCH DK, 1999, ONCOGENE, V18, P8024.MABUCHI S, 2002, J BIOL CHEM, V277, P33490, DOI 10.1074/jbc.M204042200.MADRID LV, 2000, MOL CELL BIOL, V20, P1626.MANNING BD, 2007, CELL, V129, P1261, DOI 10.1016/j.ce
25、ll.2007.06.009.MANSELL A, 2001, J BIOL CHEM, V276, P43597.MAURER U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009.MIHARA M, 2003, MOL CELL, V11, P577.MILNE D, 2004, FEBS LETT, V577, P270, DOI 10.1016/j.febslet.2004.09.081.MIRAGLIA AG, 2007, MOL BIOL CELL, V18, P2735, DOI 10.1091/mbc.E0
26、6-10-0910.MIRZA A, 2002, ONCOGENE, V21, P2613.MIYASHITA T, 1994, ONCOGENE, V9, P1799.MIZOGUCHI M, 2004, BRAIN PATHOL, V14, P372.MUNK M, 2007, BJU INT, V99, P196, DOI 10.1111/j.1464-410X.2006.06510.x.NAKATANI K, 1999, J BIOL CHEM, V274, P21528.NAKAYAMA K, 2006, CANCER BIOL THER, V5, P779.NELSON JM, 2
27、001, J BIOL CHEM, V276, P14842.NG SSW, 2000, CANCER RES, V60, P5451.NG SSW, 2001, CLIN CANCER RES, V7, P3269.NICHOLSON KM, 2002, CELL SIGNAL, V14, P381.OCONNOR DS, 2002, CANCER CELL, V2, P43.ODA K, 2005, CANCER RES, V65, P10669, DOI 10.1158/008-5472.CAN-05-2620.OGAWARA Y, 2002, J BIOL CHEM, V277, P2
28、1843.OLLIKAINEN M, 2007, INT J CANCER, V121, P915, DOI 10.1002/ijc.22768.OZES ON, 1999, NATURE, V401, P82.PALMIERI D, 2002, J BIOL CHEM, V277, P40950, DOI 10.1074/jbc.M202333200.PEDRERO JMG, 2005, INT J CANCER, V114, P242, DOI 10.1002/ijc.20711.PHILLIPS WA, 2006, INT J CANCER, V118, P2644, DOI 10.10
29、02/ijc.21706.PLO I, 1999, FEBS LETT, V452, P150.QI XJ, 2006, J BIOL CHEM, V281, P813, DOI 10.1074/jbc.M505546200.QIU LH, 2006, ONCOL REP, V16, P907.REINHARDT HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024.RICCIO A, 1999, SCIENCE, V286, P2358.ROMER MU, 2008, NEOPLASIA, V10, P1083, DO
30、I 10.1593/neo.08486.SAMUELS Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502.SASAKI H, 2000, CANCER RES, V60, P5659.SCHULER M, 2000, J BIOL CHEM, V275, P7337.SCHULER M, 2003, CELL DEATH DIFFER, V10, P451, DOI 10.1038/sj.cdd.4401180.SELVENDIRAN K, 2007, J BIOL CHEM, V282, P28609, DOI 10.1074
31、/jbc.M703796200.SERVIDEI T, 2008, INT J CANCER, V123, P2939, DOI 10.1002/ijc.23902.SHAH SA, 2001, J GASTROINTEST SURG, V5, P603.SHTILBANS V, 2008, ANN DIAGN PATHOL, V12, P153, DOI 10.1016/j.anndiagpath.2007.12.001.SINGH B, 2002, GENE DEV, V16, P984.SONG G, 2005, J CELL MOL MED, V9, P59.SORENSEN BS,
32、2004, MOL CELL BIOCHEM, V260, P129.SORENSEN BS, 2006, EXP CELL RES, V312, P3651.STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034.STAMBOLIC V, 2001, MOL CELL, V8, P317.STECK PA, 1997, NAT GENET, V15, P356.SUZUKI Y, 2001, J BIOL CHEM, V276, P27058.TAMBURINI J, 2007, BLOOD, V110, P1025, DOI 10.1182/bloo
33、d-2006-12-061283.TANAKA M, 2000, ONCOGENE, V19, P5406.TERAKAWA N, 2003, ENDOCR-RELAT CANCER, V10, P203.THOMAS S, 2005, CANCER BIOL THER, V4, P1226.TOKER A, 2000, J BIOL CHEM, V275, P8271.TOKUNAGA E, 2006, BREAST CANC, V13, P137.TOKUNAGA E, 2006, INT J CANCER, V118, P284, DOI 10.1002/ijc.21358.TORUNE
34、R M, 2006, J BIOL CHEM, V281, P8686, DOI 10.1074/jbc.M512178200.TOULANY M, 2008, MOL CANCER THER, V7, P1772, DOI 10.1158/1535-7163.MCT-07-2200.VANSCHAEYBROECK S, 2006, MOL CANCER THER, V5, P1154, DOI 10.1158/1535-7163.MCT-05-0446.VIEIRA AV, 1996, SCIENCE, V274, P2086.VILLUNGER A, 2003, SCIENCE, V302
35、, P1036, DOI 10.1126/science.1090072.WALKER KS, 1998, BIOCHEM J 1, V331, P299.WANG CY, 1998, SCIENCE, V281, P1680.WANG XH, 2004, ONCOGENE, V23, P474, DOI 10.1038/sj.onc.1207128.WENDEL HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369.WICK W, 1999, ONCOGENE, V18, P3936.WILLNER J, 2007, HUM PATHOL
36、, V38, P607, DOI 10.1016/j.humpath.2006.10.007.WILSON BE, 1996, MOL CELL BIOL, V16, P5546.WINOGRADKATZ SE, 2006, ONCOGENE, V25, P7381, DOI 10.1038/sj.onc.1209737.WU GJ, 2005, BREAST CANCER RES, V7, R609, DOI 10.1186/bcr1262.WU Z, 2008, PROSTATE, V68, P935, DOI 10.1002/pros.20745.YAMAMOTO S, 2004, CL
37、IN CANCER RES, V10, P2846.YANG H, 2006, INT J CANCER, V119, P2304, DOI 10.1002/ijc.22154.YANG JY, 2009, CLIN CANCER RES, V15, P752, DOI 10.1158/1078-0432.CCR-08-0124.YANG X, 2008, BRIT J CANCER, V98, P803, DOI 10.1038/sj.bjc.6604223.YANG XK, 2006, CANCER RES, V66, P3126.YOSHIOKA A, 2008, ONCOL REP,
38、V19, P1099.YU HG, 2008, INT J CANCER, V122, P433, DOI 10.1002/ijc.23049.ZHANG XM, 2007, INT J CANCER, V120, P1891, DOI 10.1002/ijc.22489.ZHOU BHP, 2001, NAT CELL BIOL, V3, P973.ZHOU GL, 2006, J BIOL CHEM, V281, P36443, DOI 10.1074/jbc.M600788200.ZINDA MJ, 2001, CLIN CANCER RES, V7, P2475.Cited Refer
39、ence Count: 159Times Cited: 0Publisher: ELSEVIER SINGAPORE PTE LTDPublisher Address: 3 KILLINEY ROAD 08-01, WINSLAND HOUSE 1, SINGAPORE, 239519, SINGAPOREISSN: 0929-664629-char Source Abbrev.: J FORMOS MED ASSOCISO Source Abbrev.: J. Formos. Med. Assoc.Source Item Page Count: 15Subject Category: Medicine, General & InternalISI Document Delivery No.: 426RH
